PDS Biotechnology Corp reports results for the quarter ended in December - Earnings Summary

PDS Biotechnology

27/03/2024 13:31

* PDS Biotechnology Corp  PDSB.OQ  reported a quarterly
adjusted
loss of 35 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -67 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 44 cents per
share. Wall Street expected results to range from -60 cents
to -37 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * PDS Biotechnology Corp's reported EPS for the quarter was
a loss
of 35 cents​.
    * The company reported a quarterly loss of $10.9 million.
    * PDS Biotechnology Corp shares had fallen by 9.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for PDS Biotechnology
Corp is $17.50 
This summary was machine generated from LSEG data March 27 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.44          -0.35          Beat
 Sep. 30 2023      -0.45          -0.35          Beat
 Jun. 30 2023      -0.35          -0.37          Missed
 Mar. 31 2023      -0.31          -0.32          Missed